Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H15NO4.ClH |
| Molecular Weight | 309.745 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1=CC=C(C=C1O)[C@@H]2CNCC3=C2C=CC(O)=C3O
InChI
InChIKey=NHCWZEQEFHNLBQ-PPHPATTJSA-N
InChI=1S/C15H15NO4.ClH/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20;/h1-5,10,16-20H,6-7H2;1H/t10-;/m0./s1
| Molecular Formula | C15H15NO4 |
| Molecular Weight | 273.2839 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9809482 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/9885db9d9ee078055567f91ba45eabde.html | http://adisinsight.springer.com/drugs/800002584
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/9809482 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/9885db9d9ee078055567f91ba45eabde.html | http://adisinsight.springer.com/drugs/800002584
YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.
Approval Year
Sample Use Guides
YM-435 displayed a capacity to promote cAMP formation in bovine retina when ATP/GppNHp was present. The maximally stimulated level of CAMP induced by YM 435 (210% of the controls; ATP/GppNHp only, no agonist added), was attained with 10 uM agonist. The EC50 value of YM-435-induced cAMP formation was 1.97 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:30:56 GMT 2023
by
admin
on
Sat Dec 16 05:30:56 GMT 2023
|
| Record UNII |
99I770UEI4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3078104
Created by
admin on Sat Dec 16 05:30:56 GMT 2023 , Edited by admin on Sat Dec 16 05:30:56 GMT 2023
|
PRIMARY | |||
|
99I770UEI4
Created by
admin on Sat Dec 16 05:30:56 GMT 2023 , Edited by admin on Sat Dec 16 05:30:56 GMT 2023
|
PRIMARY | |||
|
DTXSID50929974
Created by
admin on Sat Dec 16 05:30:56 GMT 2023 , Edited by admin on Sat Dec 16 05:30:56 GMT 2023
|
PRIMARY | |||
|
138086-00-7
Created by
admin on Sat Dec 16 05:30:56 GMT 2023 , Edited by admin on Sat Dec 16 05:30:56 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |